Orange Biomed to present home HbA1c testing research at ADA 2026

By AI, Created 5:56 AM UTC, May 27, 2026, /AGP/ – Orange Biomed will present late-breaking research on its microfluidic single-cell technology at the American Diabetes Association’s 86th Scientific Sessions in New Orleans on June 7, 2026. The study focuses on improving reproducibility for home-use HbA1c testing, a key hurdle for more accessible diabetes monitoring.

Why it matters: - Orange Biomed is trying to address one of the biggest barriers to home HbA1c testing: reproducibility. - Better repeatability could make diabetes monitoring more practical outside clinics and broaden access to advanced testing. - The presentation lands on the ADA’s Late-Breaking stage, a slot reserved for urgent, high-impact research.

What happened: - Orange Biomed was selected to present new research at the American Diabetes Association’s 86th Scientific Sessions in New Orleans. - The presentation is scheduled for Sunday, June 7, 2026, at 12:30 PM CT in Poster Hall, Halls D-E. - The study is titled “Improving the Reproducibility of Red Blood Cell Transit Velocity Distributions for HbA1c Estimation Using a Microfluidic Sensor” and is listed as poster #2892-LB. - The company is returning to the ADA Scientific Sessions for the fourth consecutive year.

The details: - Orange Biomed describes itself as a medical technology company behind microfluidic-based single-cell analysis technology. - The company’s flagship platform, OBM rapid A1c, is designed as a microfluidic-based HbA1c testing system for diabetes monitoring. - The research focuses on red blood cell transit velocity distributions as a way to estimate HbA1c. - The ADA Scientific Sessions runs June 5-8, 2026, and is expected to draw more than 12,000 experts from more than 110 countries. - Orange Biomed said the conference is the global stage where the future of diabetes care is shaped. - Orange Biomed is also preparing a 510(k) submission to the FDA for potential over-the-counter clearance, followed by a point-of-care application submission. - The company was recently recognized in Fortune Korea’s “Top 40 Emerging South Korean Healthcare Innovations.” - More information is available on Orange Biomed’s website.

Between the lines: - The ADA late-breaking designation suggests Orange Biomed wants to signal scientific credibility, not just product ambition. - The focus on home-use reproducibility points to a core commercial challenge: consumer testing only scales if results are consistent enough to trust. - The company’s FDA filing plans suggest Orange Biomed is positioning the technology for both consumer and point-of-care markets.

What’s next: - Orange Biomed will present the study on June 7 at the ADA meeting. - The company is expected to continue its U.S. regulatory push with the planned FDA 510(k) submission. - Orange Biomed said it wants to expand access to advanced diabetes care through its single-cell analysis technology.